文献速递肿瘤 PET/CT放射性药物与辐射防护

首次评估18F-FAZA的PET人体生物分布与剂量学:一种肿瘤乏氧显像示踪剂

First Evaluation of PET-Based Human Biodistribution and Dosimetry of 18F-FAZA, a Tracer for Imaging Tumor Hypoxia.
PubMed 文献 · J Nucl Med · 2017-02-16

这项Ⅰ期研究前瞻性纳入5例拟行手术的非小细胞肺癌患者,注射371±32 MBq 18F-FAZA后行PET/CT动态及全身显像并收集尿液,计算生物分布与辐射剂量。结果显示肌肉和肝脏摄取最高,膀胱壁为关键器官,有效剂量男性0.013±0.004、女性0.014±0.004 mSv/MBq。作者认为370 MBq注射用于临床是安全的。

要点

  • 5例非小细胞肺癌患者注射371±32 MBq 18F-FAZA后完成系列PET/CT与尿液采集。
  • 肌肉和肝脏摄取最高,%IA峰值分别为42.7±5.3 %IA和5.5±0.6 %IA,总尿排泄15 %IA。
  • 膀胱壁为关键器官,2 h与4 h排尿间隔分别为0.047±0.008和0.067±0.007 mGy/MBq。

核心结论

  • 作者认为,与现有文献相比,18F-FAZA在人体内的生物分布似乎与小鼠略有不同,人体清除率较低。
  • 作者指出,使用动物数据可能中度低估人体器官的辐射剂量。
  • 作者认为,剂量学数据显示注射370 MBq 18F-FAZA用于临床是安全的,与其他广泛使用的PET配体相似。
  • 作者指出,有效剂量与其他乏氧示踪剂如18F-氟米索硝唑相比无明显差异。

研究设计与样本

  • 这项Ⅰ期研究前瞻性纳入5例等待手术切除、组织学证实或影像学怀疑非小细胞肺癌的患者。
  • 患者注射371±32 MBq 18F-FAZA后行PET/CT,先行心脏10分钟动态采集以计算血中活性,再于注射后10、60、120、240分钟行4次全身PET/CT(从头顶至大腿中部)。
  • 每次显像后及注射后360分钟收集尿液,围绕可视源器官勾画感兴趣区生成时间-放射性曲线。
  • 由时间-放射性曲线确定停留时间,使用OLINDA/EXM 1.2对标准男性和女性体模计算各器官及全身有效剂量。

主要发现

  • 血液清除表现为快速分布后一级消除。
  • 肌肉和肝脏摄取最高,%IA峰值分别为42.7±5.3 %IA和5.5±0.6 %IA。
  • 总尿排泄为15 %IA。
  • 关键器官为膀胱壁,2小时和4小时排尿间隔的吸收剂量分别为0.047±0.008和0.067±0.007 mGy/MBq。
  • 标准男性和女性体模的有效剂量分别为0.013±0.004和0.014±0.004 mSv/MBq,取决于排尿方案。

关键数值与推荐

  • 注射活度为371±32 MBq 18F-FAZA。
  • 肌肉%IA峰值为42.7±5.3 %IA,肝脏%IA峰值为5.5±0.6 %IA。
  • 总尿排泄为15 %IA。
  • 膀胱壁吸收剂量在2小时排尿间隔为0.047±0.008 mGy/MBq,在4小时排尿间隔为0.067±0.007 mGy/MBq。
  • 标准男性体模有效剂量为0.013±0.004 mSv/MBq,标准女性体模为0.014±0.004 mSv/MBq。

临床怎么用

  • 作者认为注射370 MBq 18F-FAZA用于临床是安全的。
  • 作者指出有效剂量与其他乏氧示踪剂如18F-氟米索硝唑相比无明显差异。
  • 作者指出使用动物数据可能中度低估人体器官的辐射剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-labeled fluoroazomycinarabinoside (18F-FAZA) is a PET biomarker for noninvasive identification of regional tumor hypoxia. The aim of the present phase I study was to evaluate the biodistribution and dosimetry of 18F-FAZA in non-small cell lung cancer patients. Methods: Five patients awaiting surgical resection of histologically proven or radiologically suspected non-small cell lung cancer were prospectively enrolled in the study. The patients underwent PET/CT after injection of 371 ± 32 MBq of 18F-FAZA. The protocol consisted of a 10-min dynamic acquisition of the heart to calculate the activity in blood, followed by 4 whole-body PET/CT scans, from the vertex to the mid thigh, at 10, 60, 120, and 240 min after injection. Urine samples were collected after each imaging session and at 360 min after injection. Volumes of interest were drawn around visually identifiable source organs to generate time-activity curves. Residence times were determined from time-activity curves, and effective doses to individual organs and the whole body were calculated using OLINDA/EXM 1.2 for the standard male and female phantoms. Results: Blood clearance was characterized by a rapid distribution followed by first-order elimination. The highest uptake was in muscle and liver, with respective percentage injected activity (%IA) peaks of 42.7 ± 5.3 %IA and 5.5 ± 0.6 %IA. The total urinary excretion was 15 %IA. The critical organ, with the highest absorbed radiation doses, was the urinary bladder wall, at 0.047 ± 0.008 and 0.067 ± 0.007 mGy/MBq for the 2- and 4-h voiding intervals, respectively. The effective doses for the standard male and female phantoms were 0.013 ± 0.004 and 0.014 ± 0.004 mSv/MBq, respectively, depending on the voiding schedule. Conclusion: With respect to the available literature, the biodistribution of 18F-FAZA in humans appeared to be slightly different from that in mice, with a low clearance in humans. Therefore, use of animal data may moderately underestimate radiation doses to organs in humans. Our dosimetry data showed that a 370-MBq injection of 18F-FAZA is safe for clinical use, similar to other widely used PET ligands. In particular, the effective dose is not appreciably different from those obtained with other hypoxia tracers, such as 18F-fluoromisonidazole.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Savi A, Incerti E, Fallanca F, et al. First Evaluation of PET-Based Human Biodistribution and Dosimetry of 18F-FAZA, a Tracer for Imaging Tumor Hypoxia. J Nucl Med. 2017. PMID: 28209906. doi:10.2967/jnumed.113.122671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。